湖岸生物上涨7.24%，报1.0美元/股，总市值4121.27万美元

Core Viewpoint - Lakeshore Biosciences (LSB) has shown significant financial growth, with a notable increase in both revenue and net profit, indicating strong operational performance and potential for future investment opportunities [1]. Financial Performance - As of September 30, 2024, Lakeshore Biosciences reported total revenue of 372 million RMB, representing a year-on-year growth of 36.2% [1]. - The company's net profit attributable to shareholders reached 20.58 million RMB, marking a substantial increase of 111.79% compared to the previous year [1]. Company Overview - Lakeshore Biosciences is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1]. - The company is a global biopharmaceutical firm focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].